Short Term Effects of a Multimodal Intervention With RGM on Cognition in People With Parkinson's Disease.
The goal of this clinical trial is to learn if the Ronnie Gardiner Method (RGM) works to improve cognitive functions in adults with Parkinson's disease (early to mid-stage). It will also learn about the secondary effects on speech, mobility, balance, and mood. The main questions it aims to answer are: * Does a 10-week RGM intervention improve cognitive aspects, speech (indirectly through improved breathing), mobility, and balance in participants with Parkinson's disease? * How do participants experience the intensity, difficulty, and emotional impact of the RGM sessions?
Study identifier: NCT07863219. Status: RECRUITING. Phase: NA.
Eligibility
Criteria: Inclusion Criteria: * diagnosis of idiopathic Parkinson's disease * safe, independent mobility and participation (Hoehn and Yahr stages 1-3) * a stable dopaminergic medication regimen for at least 4 weeks prior to study participation * willingness and ability to participate in a 10-week intervention program * willingness to participate in the study (signing of informed consent) Exclusion Criteria: * Presence of other neurological or severe psychiatric conditions that could interfere with participation or the interpretation of results (e.g., substance use disorder, severe depression, psychosis) * Severe visual or hearing impairments that limit the ability to follow group instructions as determined by a physician. * Physical limitations that inhibit safe participation in moderate-to-vigorous exercise or group rehabilitation.
- Minimum age: 18 Years
Participating locations
- University Hospital Ghent, Ghent, Oost-Vlaanderen
Study records are sourced from ClinicalTrials.gov. Confirm current eligibility, recruiting status, and locations in the official record.